Afatinib and Erlotinib in the treatment of squamous-cell lung cancer
M Tagliamento, C Genova, E Rijavec… - Expert Opinion on …, 2018 - Taylor & Francis
Introduction Squamous-cell carcinoma (SCC) of the lung represents around 20% of non-
small cell lung cancers. Although activating mutations of EGFR are rare in this subtype, its …
small cell lung cancers. Although activating mutations of EGFR are rare in this subtype, its …
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.
M Tagliamento, C Genova, E Rijavec… - Expert Opinion on …, 2018 - europepmc.org
Squamous-cell carcinoma (SCC) of the lung represents around 20% of non-small cell lung
cancers. Although activating mutations of EGFR are rare in this subtype, its overexpression …
cancers. Although activating mutations of EGFR are rare in this subtype, its overexpression …
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer
M Tagliamento, C Genova, E Rijavec… - EXPERT OPINION …, 2018 - irinsubria.uninsubria.it
Introduction: Squamous-cell carcinoma (SCC) of the lung represents around 20% of non-
small cell lung cancers. Although activating mutations of EGFR are rare in this subtype, its …
small cell lung cancers. Although activating mutations of EGFR are rare in this subtype, its …
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer
M Tagliamento, C Genova, E Rijavec… - Expert opinion on …, 2018 - pubmed.ncbi.nlm.nih.gov
Introduction Squamous-cell carcinoma (SCC) of the lung represents around 20% of non-
small cell lung cancers. Although activating mutations of EGFR are rare in this subtype, its …
small cell lung cancers. Although activating mutations of EGFR are rare in this subtype, its …